Scientists on the Florida campus of The Scripps Research Institute (TSRI) have improved a state-of-the-art gene-editing technology to advance the system’s ability to target, cut and paste genes within human and animal cells—and broadening the ways the CRISPR-Cpf1 editing system may be used to study and fight human diseases.
Professor Michael Farzan, co-chair of TSRI’s Department of Immunology and Microbiology, and TSRI Research Associate Guocai Zhong improved the efficiency of the CRISPR-Cpf1 gene editing system by incorporating guide RNAs with “multiplexing” capability. Guide RNAs are short nucleic acid strings that lead the CRISPR molecular scissors to their intended gene targets. The TSRI discovery means multiple genetic targets in a cell may be hit by each CRISPR-Cpf1 complex.
“This system simplifies and significantly improves the efficiency of simultaneous editing of multiple genes, or multiple sites of a single gene,” Zhong said. “This could be very useful when multiple disease-related genes or multiple sites of a disease-related gene need to be targeted.”
“This approach improves gene editing for a number of applications,” Farzan added. “The system makes some applications more efficient and other applications possible.”
This study was published as an advanced online paper in the journal Nature Chemical Biology on June 19, 2017.
TSRI Advance Makes CRISPR More Efficient
Short for “Clustered Regularly Interspaced Short Palindromic Repeat,” the CRISPR gene editing system exploits an ancient bacterial immune defense process. Some microbes thwart viral infection by sequestering a piece of a virus’ foreign genetic material within its own DNA, to serve as a template. The next time the viral sequence is encountered by the microbe, it’s recognized immediately and cut up for disposal with the help of two types of RNA. Molecules called guide RNAs provide the map to the invader, and CRISPR effector proteins act as the scissors that cut it apart.
Over the last five years, the CRISPR gene editing system has revolutionized microbiology and renewed hopes that genetic engineering might eventually become a useful treatment for disease. But time has revealed the technology’s limitations. For one, gene therapy currently requires using a viral shell to serve as the delivery package for the therapeutic genetic material. The CRISPR molecule is simply too large to fit with multiple guide RNAs into the most popular and useful viral packaging system.
The new study from Farzan and colleagues helps solve this problem by letting scientists package multiple guide RNAs.
This advance could be important if gene therapy is to treat diseases such as hepatitis B, Farzan said. After infection, hepatitis B DNA sits in liver cells, slowly directing the production of new viruses, ultimately leading to liver damage, cirrhosis and even cancer. The improved CRISPR-Cpf1 system, with its ability to ‘multiplex,’ could more efficiently digest the viral DNA, before the liver is irrevocably damaged, he said.
“Efficiency is important. If you modify 25 cells in the liver, it is meaningless. But if you modify half the cells in the liver, that is powerful,” Farzan said. “There are other good cases—say muscular dystrophy—where if you can repair the gene in enough muscle cells, you can restore the muscle function.”
Two types of these molecular scissors are now being widely used for gene editing purposes: Cas9 and Cpf1. Farzan said he focused on Cpf1 because it is more precise in mammalian cells. The Cpf1 molecule they studied was sourced from two types of bacteria, Lachnospiraceae bacterium and Acidaminococus sp., whose activity has been previously studied in E. coli. A key property of these molecules is they are able to grab their guide RNAs out of a long string of such RNA; but it was not clear that it would work with RNA produced from mammalian cells. Guocai tested this idea by editing a firefly bioluminescence gene into the cell’s chromosome. The modified CRISPR-Cpf1 system worked as anticipated.
“This means we can use simpler delivery systems for directing the CRISPR effector protein plus guide RNAs,” Farzan said. “It’s going to make the CRISPR process more efficient for a variety of applications.”
Looking forward, Farzan said the Cpf1 protein needs to be more broadly understood so that its utility in delivering gene therapy vectors can be further expanded.
The Latest on: CRISPR-Cpf1
- Cross-reactivity and inclusivity analysis of CRISPR-based diagnostic assays of coronavirus SARS-CoV-2on October 1, 2021 at 7:24 am
Its diagnosis relies on the molecular detection of the viral RNA by polymerase chain reaction (PCR) while newer rapid CRISPR-based diagnostic tools are being developed. As molecular diagnostic assays ...
- At 23.95% CAGR, CRISPR Market Size is Projected to be Around US$ 5872.4 million by 2028on September 30, 2021 at 7:59 pm
Oct 01, 2021 (Market Insight Reports) -- Global CRISPR Market Report added at Market Study Report offers industry size, share, growth, trends and forecast analysis up to 2028. CRISPR Market Report ...
- Crispr Market Size, Analysis, Competitive Strategies and Forecasts to 2028on September 27, 2021 at 4:18 am
Sep 27, 2021 (Market Insight Reports) -- Global Crispr market analysis mainly introduces the changing market dynamics in terms of covering all details inside analysis and opinion, volume and value ...
- CRISPR Update Could Make Gene Edits Easier, Discoverers Sayon September 24, 2021 at 5:00 pm
They say it might help overcome some of the difficulties researchers have run into as they develop CRISPR-related treatments for human diseases. That said, the Cpf1 work is still in its infancy.
- Aiming for better genetic medicines delivery, startup GenEdit grabs $26Mon September 23, 2021 at 9:27 pm
Adeno-associated virus is a workhorse of genetic medicine, serving as the delivery vehicle for a slew of approved and experimental therapies. But adverse effects are a known risk of AAV; injuries ...
- Editas Medicine to Participate in Upcoming Investor Conferenceson September 2, 2021 at 1:00 am
The events will be webcast live and can be accessed on the Editas Medicine website in the Investors section. Archived recordings will be available for approximately 30 days following the events.
- Generation of Knock-in Mice Using Single-Stranded Oligodeoxynucleotides (ssODNs)on December 18, 2020 at 4:06 am
At this time, the Core can perform genome editing with S.p. Cas9 or A.s. Cas12a/Cpf1. The targeting will be done in embryos using electroporation to introduce the CRISPR reagents. The User ...
- EDIT.OQ - Editas Medicine Inc Profile | Reuterson August 12, 2020 at 7:07 pm
or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The Company is focused on both in vivo ...
- Improved gene-editing precision to boost Japan’s bioeconomyon August 5, 2020 at 9:33 pm
CRISPR-Cpf1 and CRISPR-Cas3, but many CRISPR families are yet to be fully explored as genome editing tools, says Nakamura. Tokushima University researchers developed their tool by examining Cas ...
- Generation of Knockout Mice using Electroporationon July 31, 2020 at 5:30 pm
CRISPR/Cas9-mediated NHEJ in mouse embryos will be used to generate founder animals harboring insertion/deletion (indel) or interval deletion knockout alleles. At this time, the Core can perform ...
via Google News and Bing News